Synthetic Lethality-Based Drugs and Targets Market Size to Hit USD 9.37 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Synthetic Lethality-Based Drugs and Targets Market

5.1. COVID-19 Landscape: Synthetic Lethality-Based Drugs and Targets Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Synthetic Lethality-Based Drugs and Targets Market, By Drug Type

8.1. Synthetic Lethality-Based Drugs and Targets Market, by Drug Type

8.1.1. Small Molecules

8.1.1.1. Market Revenue and Forecast

8.1.2. Biologics

8.1.2.1. Market Revenue and Forecast

Chapter 9. Global Synthetic Lethality-Based Drugs and Targets Market, By Target Type

9.1. Synthetic Lethality-Based Drugs and Targets Market, by Target Type

9.1.1. PARP Inhibitors

9.1.1.1. Market Revenue and Forecast

9.1.2. ATR Inhibitors

9.1.2.1. Market Revenue and Forecast

9.1.3. DNA Damage Repair Targets

9.1.3.1. Market Revenue and Forecast

9.1.4. Others

9.1.4.1. Market Revenue and Forecast

Chapter 10. Global Synthetic Lethality-Based Drugs and Targets Market, By Application

10.1. Synthetic Lethality-Based Drugs and Targets Market, by Application

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast

10.1.2. Genetic Disorders

10.1.2.1. Market Revenue and Forecast

10.1.3. Others

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Synthetic Lethality-Based Drugs and Targets Market, By End-User

11.1. Synthetic Lethality-Based Drugs and Targets Market, by End-User

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast

11.1.2. Specialty Clinics

11.1.2.1. Market Revenue and Forecast

11.1.3. Research Institutes

11.1.3.1. Market Revenue and Forecast

11.1.4. Others

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Synthetic Lethality-Based Drugs and Targets Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Drug Type

12.1.2. Market Revenue and Forecast, by Target Type

12.1.3. Market Revenue and Forecast, by Application

12.1.4. Market Revenue and Forecast, by End-User

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Drug Type

12.1.5.2. Market Revenue and Forecast, by Target Type

12.1.5.3. Market Revenue and Forecast, by Application

12.1.5.4. Market Revenue and Forecast, by End-User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Drug Type

12.1.6.2. Market Revenue and Forecast, by Target Type

12.1.6.3. Market Revenue and Forecast, by Application

12.1.6.4. Market Revenue and Forecast, by End-User

12.2. Europe

12.2.1. Market Revenue and Forecast, by Drug Type

12.2.2. Market Revenue and Forecast, by Target Type

12.2.3. Market Revenue and Forecast, by Application

12.2.4. Market Revenue and Forecast, by End-User

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Drug Type

12.2.5.2. Market Revenue and Forecast, by Target Type

12.2.5.3. Market Revenue and Forecast, by Application

12.2.5.4. Market Revenue and Forecast, by End-User

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Drug Type

12.2.6.2. Market Revenue and Forecast, by Target Type

12.2.6.3. Market Revenue and Forecast, by Application

12.2.6.4. Market Revenue and Forecast, by End-User

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Drug Type

12.2.7.2. Market Revenue and Forecast, by Target Type

12.2.7.3. Market Revenue and Forecast, by Application

12.2.7.4. Market Revenue and Forecast, by End-User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Drug Type

12.2.8.2. Market Revenue and Forecast, by Target Type

12.2.8.3. Market Revenue and Forecast, by Application

12.2.8.4. Market Revenue and Forecast, by End-User

12.3. APAC

12.3.1. Market Revenue and Forecast, by Drug Type

12.3.2. Market Revenue and Forecast, by Target Type

12.3.3. Market Revenue and Forecast, by Application

12.3.4. Market Revenue and Forecast, by End-User

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Drug Type

12.3.5.2. Market Revenue and Forecast, by Target Type

12.3.5.3. Market Revenue and Forecast, by Application

12.3.5.4. Market Revenue and Forecast, by End-User

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Drug Type

12.3.6.2. Market Revenue and Forecast, by Target Type

12.3.6.3. Market Revenue and Forecast, by Application

12.3.6.4. Market Revenue and Forecast, by End-User

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Drug Type

12.3.7.2. Market Revenue and Forecast, by Target Type

12.3.7.3. Market Revenue and Forecast, by Application

12.3.7.4. Market Revenue and Forecast, by End-User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Drug Type

12.3.8.2. Market Revenue and Forecast, by Target Type

12.3.8.3. Market Revenue and Forecast, by Application

12.3.8.4. Market Revenue and Forecast, by End-User

12.4. MEA

12.4.1. Market Revenue and Forecast, by Drug Type

12.4.2. Market Revenue and Forecast, by Target Type

12.4.3. Market Revenue and Forecast, by Application

12.4.4. Market Revenue and Forecast, by End-User

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Drug Type

12.4.5.2. Market Revenue and Forecast, by Target Type

12.4.5.3. Market Revenue and Forecast, by Application

12.4.5.4. Market Revenue and Forecast, by End-User

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Drug Type

12.4.6.2. Market Revenue and Forecast, by Target Type

12.4.6.3. Market Revenue and Forecast, by Application

12.4.6.4. Market Revenue and Forecast, by End-User

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Drug Type

12.4.7.2. Market Revenue and Forecast, by Target Type

12.4.7.3. Market Revenue and Forecast, by Application

12.4.7.4. Market Revenue and Forecast, by End-User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Drug Type

12.4.8.2. Market Revenue and Forecast, by Target Type

12.4.8.3. Market Revenue and Forecast, by Application

12.4.8.4. Market Revenue and Forecast, by End-User

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Drug Type

12.5.2. Market Revenue and Forecast, by Target Type

12.5.3. Market Revenue and Forecast, by Application

12.5.4. Market Revenue and Forecast, by End-User

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Drug Type

12.5.5.2. Market Revenue and Forecast, by Target Type

12.5.5.3. Market Revenue and Forecast, by Application

12.5.5.4. Market Revenue and Forecast, by End-User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Drug Type

12.5.6.2. Market Revenue and Forecast, by Target Type

12.5.6.3. Market Revenue and Forecast, by Application

12.5.6.4. Market Revenue and Forecast, by End-User

Chapter 13. Company Profiles

13.1. AstraZeneca

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. GlaxoSmithKline

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Pfizer

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Merck & Co.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Bristol-Myers Squibb

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Novartis

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Roche

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Eli Lilly and Company

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Sanofi

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Johnson & Johnson

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The synthetic lethality-based drugs and targets market size is expected to increase from USD 1.86 billion in 2025 to USD 9.37 billion by 2035.

Answer : The synthetic lethality-based drugs and targets market is expected to grow at a compound annual growth rate (CAGR) of around 17.52% from 2026 to 2035.

Answer : The major players in the synthetic lethality-based drugs and targets market include AstraZeneca, GlaxoSmithKline, Pfizer, Merck & Co., Bristol-Myers Squibb, Novartis, Roche, Eli Lilly and Company, Sanofi, Johnson & Johnson, Tesaro, Repare Therapeutics, IDEAYA Biosciences, Artios Pharma, Bayer AG, Takeda Pharmaceutical, Celgene Corporation, AbbVie, Amgen, and Clovis Oncology.

Answer : The driving factors of the synthetic lethality-based drugs and targets market are the the surging demand for cancer treatments, coupled with growing pharmaceutical research and development activities.

Answer : North America region will lead the global synthetic lethality-based drugs and targets market during the forecast period 2026 to 2035.